The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of complicated urinary tract infection. Leading companies like Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, and others are developing drugs for complicated urinary tract infection treatment.
LAS VEGAS, Sept. 12, 2022 /PRNewswire/ -- DelveInsight's Complicated Urinary Tract Infections Market Insights report includes a comprehensive understanding of current treatment practices, complicated urinary tract infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].
Key Takeaways from the Complicated Urinary Tract Infections Market Report
- As per DelveInsight analysis, the complicated urinary tract infections market size in the 7MM was approximately USD 1,870 million in 2021.
- As per the estimates, the total complicated urinary tract infections diagnosed incident population in the 7MM was approximately 8 million in 2021.
- Leading complicated urinary tract infections companies such as Merck Sharp & Dohme, AbbVie, Pfizer, Shionogi, Melinta Therapeutics, Cipla Therapeutics, Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, and others are developing novel complicated urinary tract infections drugs that can be available in the complicated urinary tract infections market in the upcoming years.
- The complicated urinary tract infections therapies in the pipeline include Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime-zidebactam (WCK-5222), Cefepime/Taniborbactam, Cefepime/Enmetazobactam, Fosfomycin (ZT-01/Contempo), Finafloxacin, and others.
- The increase in complicated urinary tract infections market size is a direct consequence of an increase in R&D activity, increasing prevalent population, and expected commercial success of upcoming therapies.
Discover which therapies are expected to grab major complicated urinary tract infections market share @Complicated Urinary Tract Infections Market Report
Complicated Urinary Tract Infections Overview
Urinary tract infections (UTIs) are among the most common bacterial infections. Clinically, they can manifest in various ways, ranging from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a multifaceted entity with numerous forms. Infection from microorganisms is among the major complicated urinary tract infections causes.
Complicated urinary tract infection symptoms such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort are the most important clinical criteria for the initial complicated urinary tract infection diagnosis. Furthermore, there must be a suitable clinical scenario in which the most likely cause of these complicated urinary tract infection symptoms is a urogenital tract infection.
The complicated urinary tract infections treatment goals are to eliminate the infection, avoid complications, and provide symptomatic relief. Early complicated urinary tract infection treatment is recommended to reduce the risk of developing pyelonephritis.
Complicated Urinary Tract Infections Epidemiology Segmentation
As per DelveInsight, there were approximately 8 million complicated urinary tract infections diagnosed incident cases in the 7MM in 2021.
Among the 7MM, the US had recorded the highest diagnosed incidence of complicated urinary tract infections in 2021.
The complicated urinary tract infections market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diagnosed-incident Cases of Complicated Urinary Tract Infection
- Total Age-specific Cases of Complicated Urinary Tract Infection
- Total Treated Cases of Complicated Urinary Tract Infection
- Total Pathogen-specific Cases of Complicated Urinary Tract Infection
Download the report to understand which factors are driving complicated urinary tract infections epidemiology trends @Complicated Urinary Tract Infections Epidemiological Insights
Complicated Urinary Tract Infections Treatment Market
Complicated UTIs are treated with broader antimicrobial coverage and may require intravenous antibiotics depending on severity. For difficult lower UTIs, broad-spectrum antibiotic therapy should be used for 7–14 days and curable underlying causes should be treated. Recurrent UTIs are common in women, and antibiotic prophylaxis may be recommended. Catheter-associated urinary tract infection (CAUTI) is one of the most common infections associated with healthcare, and it is treated with catheter removal or replacement as well as antibiotic medication. CAUTIs are frequently caused by resistant bacteria. Pregnant women should be tested and treated for UTIs and asymptomatic bacteriuria, respectively.
Moreover, Avycaz was approved in the United States in February 2015 for the treatment of adult patients with complex urinary tract infections (cUTI), including pyelonephritis, caused by identified susceptible bacteria such as certain Enterobacteriaceae and Pseudomonas aeruginosa. It was approved in Europe in June 2016. The company expanded its label for pediatric patients in the US market in March 2019 and in Europe in November 2020. Allergan and Abbvie have US rights to the drug's development, while Pfizer has market rights outside of the US. The only drugs approved for adult and pediatric patient pools are Zerbaxa and Avycaz. Other drugs approved by the FDA and EMA for complicated urinary tract infection treatment include Recarbrio (Merck), Fetroja (Shionogi), Vabomere (Melinta therapeutics), and Zemdri (Cipla therapeutics).
To know more about complicated urinary tract infections treatment options, visit @New Treatment for Complicated Urinary Tract Infections
Complicated Urinary Tract Infections Pipeline Therapies and Key Companies
- Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics
- Cefepime-zidebactam (WCK-5222): Wockhardt
- Cefepime/Taniborbactam: Venatorx Pharmaceuticals
- Cefepime/Enmetazobactam: Allecra Therapeutics
- Fosfomycin (ZT-01/Contempo): Nabriva Therapeutics AG
- Finafloxacin: MerLion Pharmaceuticals
Learn more about the complicated urinary tract infections therapies in clinical trials @Drugs for Complicated Urinary Tract Infections Treatment
Complicated Urinary Tract Infections Market Dynamics
With increasing multidrug resistance and antibiotic overuse, the prevalence of cUTIs is expected to rise in the future, propelling the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for cUTI is expected to aid complicated urinary tract infections market growth.
Moreover, antibiotics are in high demand as they are the only treatment for cUTIs and UTIs. There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market. Furthermore, increased mergers/acquisitions and collaborations between companies to develop safe and effective drugs will accelerate complicated urinary tract infections market growth.
However, inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus impeding the growth of the complicated urinary tract infections market.
Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to impede clinical trial study evaluation in the complicated urinary tract infections market.
As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis, complex regulatory requirements are expected to hinder the growth of the complicated urinary tract infections market.
Furthermore, conflicting guidelines on uncomplicated urinary tract infections issued by various organizations cause confusion among providers that will further impact the growth of the complicated urinary tract infections market.
Scope of the Complicated Urinary Tract Infections Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Complicated Urinary Tract Infections Companies: Merck Sharp & Dohme, AbbVie, Pfizer, Shionogi, Melinta Therapeutics, Cipla Therapeutics, Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, and others
- Key Complicated Urinary Tract Infections Therapies: Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime-zidebactam (WCK-5222), Cefepime/Taniborbactam, Cefepime/Enmetazobactam, Fosfomycin (ZT-01/Contempo), Finafloxacin, and others
- Therapeutic Assessment: Complicated Urinary Tract Infections current marketed and emerging therapies
- Complicated Urinary Tract Infections Market Dynamics: Complicated Urinary Tract Infections market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Complicated Urinary Tract Infections Market Access and Reimbursement
Discover more about drugs for complicated urinary tract infections in development @Complicated Urinary Tract Infections Clinical Trials
Table of Contents
1. | Complicated Urinary Tract Infections Market Key Insights |
2. | Complicated Urinary Tract Infections Market Report Introduction |
3. | Complicated Urinary Tract Infections Market Overview at a Glance |
4. | Complicated Urinary Tract Infections Market Executive Summary |
5. | Disease Background and Overview |
6. | Complicated Urinary Tract Infections Treatment and Management |
7. | Complicated Urinary Tract Infections Epidemiology and Patient Population |
8. | Patient Journey |
9. | Complicated Urinary Tract Infections Marketed Drugs |
10. | Complicated Urinary Tract Infections Emerging Drugs |
11. | Seven Major Complicated Urinary Tract Infections Market Analysis |
12. | Complicated Urinary Tract Infections Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Complicated Urinary Tract Infections Market Drivers |
16. | Complicated Urinary Tract Infections Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Get in touch with our business executive @Healthcare Due Diligence Services
Related Reports
Complicated Urinary Tract Infections Epidemiology Forecast
Complicated Urinary Tract Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the complicated urinary tract infections epidemiology trends.
Complicated Urinary Tract Infections Pipeline
Complicated Urinary Tract Infections Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key complicated urinary tract infections companies, including Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, among others.
Uncomplicated Urinary Tract Infections Pipeline
Uncomplicated Urinary Tract Infections Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key uncomplicated urinary tract infections companies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.
Uncomplicated Urinary Tract Infections Market
Uncomplicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key uncomplicated urinary tract infections companies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.
Uncomplicated Urinary Tract Infections Epidemiology
Uncomplicated Urinary Tract Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the uncomplicated urinary tract infections epidemiology trends.
Other Trending Reports
Diagnostic Imaging Equipment Market | Invasive Candidiasis Market | Sialidosis Market | Filgrastim Biosimilar Insight | Pain Management Devices Market | Primordial Dwarfism Market | Non-cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Cystinuria Market | Deep Vein Thrombosis Market | Acquired Immunodeficiency Syndrome Market | Gene and Cell Therapies in Rare Disorder Market | Pediatric Growth Hormone Deficiency (PGHD) Market | Pain Management Devices Market | Diagnostic Imaging Equipment Market | Ischemic Stroke Market | Paget's Disease Market | Resorbable Vascular Scaffold Market | Rosai–Dorfman disease (RDD) Market | Salivary Gland Infection Market | Sandhoff Disease Market | Scedosporium Infection Market | Structural Heart Devices Market | Vascular Graft Devices Market | Vascular Stents Market | Vein Illumination Devices Market | Ventricular Assist Devices (VAD) Market | Adrenocortical Carcinoma Market | Cystinuria Market | Myopia Treatment Devices Market | Urology Ultrasounds Devices Market | Sly Syndrome Market | Human Papillomavirus-Positive Oropharyngeal | Cancer Market | Tuberculosis Market | Plasmodium Vivax Malaria Market | Oncolytic Virus Cancer Therapy Pipeline | Facial Lines Market | Rosacea Market | Polycystic Kidney Disease Market | Oropharyngeal Cancer Market | NPC Market | Immune Thrombocytopenia Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
